Hologic Inc.05.18.16
Hologic Inc. is expanding its MyoSure suite of gynecologic surgical products to include the MyoSure REACH device, a product that confronts the challenge of hard-to-reach uterine pathology by enabling access to the upper third of the uterine cavity1.
“The ability to remove hard-to-reach intrauterine pathology is an important enhancement for the MyoSure system, and it demonstrates Hologic’s dedication to women's health,” said Edward Evantash, M.D., medical director and vice president of medical affairs at Hologic. “The MyoSure REACH device offers the benefits of the current device, plus expanded capabilities to remove pathology in the upper third of the uterine cavity.”
The MyoSure tissue removal system is designed to offer a simple and quick solution for women with polyps and fibroids, which often cause abnormal uterine bleeding (AUB). AUB is estimated to affect 11 percent to 13 percent of reproductive-age women and nearly 24 percent of women ages 36 to 402, according to industry data. The MyoSure REACH device features a shortened distance from the distal tip to the cutting window of less than 1 millimeter. When compared to the predecessor device, the new design has been shown to get three times closer to the uterine wall and removes 25 percent more tissue in a simulated bench top model3. Other devices in the MyoSure suite of products include the MyoSure, MyoSure XL, and MyoSure LITE devices.
“The MyoSure REACH device helps physicians better meet the needs of their patients by providing them an efficient and effective solution for pathology removal,” said Tom O’Neill, Hologic’s division president, GYN Surgical Solutions. “The MyoSure REACH device is an exciting addition to Hologic’s suite of gynecologic solutions, which are quick and effective for physicians and patients.”
Hologic develops, manufactures and supplies premium diagnostic products, medical imaging systems and surgical products. The Marlborough, Mass.-based company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.
References:
1. Di Spiezio Sardo A, Calagna G, Guida M, Perino A, Nappi C. Hysteroscopy and treatment of uterine polyps. Best Pract Res Clin Obstet Gynaecol. 2015;29:908-919.
2. Primary Care Management of Abnormal Uterine Bleeding. Agency for Health Care Research and Quality website http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1431&pageaction=displayproduct. Updated March 21, 2013. Accessed April 25, 2016.
3. Based on internal bench testing that measured average relative height change of simulated 2-cm diameter tissue resected from a uterine model by 11 surgeon users - See more at: http://media.hologic.com/2016-05-11-Hologic-Introduces-the-MyoSure-REACH-Device-to-Help-Physicians-Access-the-Hard-to-Reach-Upper-Third-of-the-Uterine-Cavity#sthash.TnAqGx5D.dpuf
“The ability to remove hard-to-reach intrauterine pathology is an important enhancement for the MyoSure system, and it demonstrates Hologic’s dedication to women's health,” said Edward Evantash, M.D., medical director and vice president of medical affairs at Hologic. “The MyoSure REACH device offers the benefits of the current device, plus expanded capabilities to remove pathology in the upper third of the uterine cavity.”
The MyoSure tissue removal system is designed to offer a simple and quick solution for women with polyps and fibroids, which often cause abnormal uterine bleeding (AUB). AUB is estimated to affect 11 percent to 13 percent of reproductive-age women and nearly 24 percent of women ages 36 to 402, according to industry data. The MyoSure REACH device features a shortened distance from the distal tip to the cutting window of less than 1 millimeter. When compared to the predecessor device, the new design has been shown to get three times closer to the uterine wall and removes 25 percent more tissue in a simulated bench top model3. Other devices in the MyoSure suite of products include the MyoSure, MyoSure XL, and MyoSure LITE devices.
“The MyoSure REACH device helps physicians better meet the needs of their patients by providing them an efficient and effective solution for pathology removal,” said Tom O’Neill, Hologic’s division president, GYN Surgical Solutions. “The MyoSure REACH device is an exciting addition to Hologic’s suite of gynecologic solutions, which are quick and effective for physicians and patients.”
Hologic develops, manufactures and supplies premium diagnostic products, medical imaging systems and surgical products. The Marlborough, Mass.-based company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.
References:
1. Di Spiezio Sardo A, Calagna G, Guida M, Perino A, Nappi C. Hysteroscopy and treatment of uterine polyps. Best Pract Res Clin Obstet Gynaecol. 2015;29:908-919.
2. Primary Care Management of Abnormal Uterine Bleeding. Agency for Health Care Research and Quality website http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1431&pageaction=displayproduct. Updated March 21, 2013. Accessed April 25, 2016.
3. Based on internal bench testing that measured average relative height change of simulated 2-cm diameter tissue resected from a uterine model by 11 surgeon users - See more at: http://media.hologic.com/2016-05-11-Hologic-Introduces-the-MyoSure-REACH-Device-to-Help-Physicians-Access-the-Hard-to-Reach-Upper-Third-of-the-Uterine-Cavity#sthash.TnAqGx5D.dpuf
1 Di Spiezio Sardo A, Calagna G, Guida M, Perino A, Nappi C. Hysteroscopy and treatment of uterine polyps. Best Pract Res Clin Obstet Gynaecol. 2015;29:908-919.
2 Primary Care Management of Abnormal Uterine Bleeding. Agency for Health Care Research and Quality website http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1431&pageaction=displayproduct. Updated March 21, 2013. Accessed April 25, 2016.
3 Based on internal bench testing that measured average relative height change of simulated 2-cm diameter tissue resected from a uterine model by 11 surgeon users - See more at: http://media.hologic.com/2016-05-11-Hologic-Introduces-the-MyoSure-REACH-Device-to-Help-Physicians-Access-the-Hard-to-Reach-Upper-Third-of-the-Uterine-Cavity#sthash.TnAqGx5D.dpuf
2 Primary Care Management of Abnormal Uterine Bleeding. Agency for Health Care Research and Quality website http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=1431&pageaction=displayproduct. Updated March 21, 2013. Accessed April 25, 2016.
3 Based on internal bench testing that measured average relative height change of simulated 2-cm diameter tissue resected from a uterine model by 11 surgeon users - See more at: http://media.hologic.com/2016-05-11-Hologic-Introduces-the-MyoSure-REACH-Device-to-Help-Physicians-Access-the-Hard-to-Reach-Upper-Third-of-the-Uterine-Cavity#sthash.TnAqGx5D.dpuf